Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies
Launched by INSTITUTE OF APPLIED BIOSCIENCES · Oct 15, 2024
Trial Information
Current as of August 29, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The goal of this observational study is to address the role of T cells in the tumor microenvironment of TNBC.
In detail, this study aims to:
(i) explore the immunogenetic characteristics of the TR gene repertoire as informative prognostic/predictive biomarkers in TNBC (ii) identify immunogenic neoepitopes arising from common tumor-specific non-synonymous gene mutations, as well as the corresponding neoepitope-specific T cells (iii) describe, in single-cell resolution, the spatial organization of the intricate crosstalk between tumor cells and neoepitope specific-T cells, and (iv) delineat...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • - Confirmed TNBC diagnosis
- Exclusion Criteria:
- • -
About Institute Of Applied Biosciences
The Institute of Applied Biosciences is a leading research organization dedicated to advancing the field of biomedical sciences through innovative clinical trials and research initiatives. With a strong emphasis on translating scientific discoveries into practical applications, the institute collaborates with academic, industry, and healthcare partners to develop novel therapies and improve patient outcomes. Its commitment to rigorous scientific methodology and ethical standards ensures the integrity and reliability of its clinical trials, positioning the institute as a trusted sponsor in the biosciences community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Thessaloniki, , Greece
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported